sglt2 glp-1 news Diabetic Agents, From Metformin to Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar GLP-1 and SGLT2 inhibitors show

This class of medications is becoming a household name, not only for their implications for weight loss but also for their effect on cardiovascular disease

For patients using compounded semaglutide from PlexusDx, each month covers four weekly doses at a flat rate at $189/mo month-to-month, or from $149/mo on the 6-month planyour dose may need to go up, but your price won't

We often see patients describe reduced food noise, improved portion awareness, and a greater sense of control around meals

Sekhar RV

mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation

GLP-1 medications (like semaglutide and tirzepatide) can deliver major scale results